NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Battle of the NASH Thrones Investor Conference on Wednesday, October 17, 2018 at the Park Hyatt Hotel in New York City.
ROTH’s Battle of the NASH Thrones Investor Conference will give investors the opportunity to interact with senior management of a select group of prominent public and private companies focused on Non-alcoholic Steatohepatitis (NASH). Yasmeen Rahimi, Ph.D., Managing Director, Senior Research Analyst, will also be moderating four panel discussions on topics that are currently at the forefront of NASH. The panel “Demystifying NASH Diagnosis and Pricing” will tackle NASH drug pricing as the field heads into the first potential approvals in 2019 and will feature a variety of stakeholders, including the Global Liver Institute, consultants and senior management representatives, as well as expert physicians. The panels “House of FXRs vs. House of FGFs,” “House of PPARs vs. House of THR-beta,” and “Younglings and Elders of the Fibrotic, Inflammatory, and Metabolic Agents: the Powers vs. Wheel breakers” will feature discussions revolving around key mechanisms of action in NASH, with the expert opinions of five key opinion leaders who are renowned in their respective areas.
ROTH has built a leading Healthcare Investment Banking Group over the
last several years and has raised approximately $15+ billion in over 400
Healthcare transactions since 2010.
*Past Performance is not indicative of future returns. (Source: ROTH Capital Partners | 10/01/2018)
The event is for institutional clients of ROTH and is by invitation only. For more information, please contact your ROTH sales representative at (949) 720-5700 or e-mail: email@example.com.
Agenda and Events:
7:00am - 8:00am | Registration & Morning Coffee
7:45am - 8:00am | Introduction by Yasmeen Rahimi, Ph.D.
8:00am - 4:00pm | Panels
9:00am - 5:00pm | 1-on-1 / Small Group Meetings (excluding panel times)
12:00pm - 1:00pm | Working Lunch
5:00pm - 7:00pm | Cocktail Reception (Bevy @ Park Hyatt New York)
Park Hyatt New York
153 W 57th St, New York, NY 10019
The following participating companies are confirmed as of the date of this release:
|3-V Biosciences PRIVATE|
|Akero Therapeutics PRIVATE|
|Albireo Pharma (ALBO)|
|American Liver Foundation|
|Conatus Pharmaceuticals (CNAT)|
|CymaBay Therapeutics (CBAY)|
|Enanta Pharmaceuticals (ENTA)|
|Galectin Therapeutics, Inc (GALT)|
|Galmed Pharmaceuticals (GLMD)|
|Gemphire Therapeutics (GEMP)|
|GENFIT S.A. (GNFT.PA)|
|Genkyotex S.A. (GKTX.PA)|
|Global Liver Institute|
|Intercept Pharmaceuticals (ICPT)|
|Inventiva S.A. (IVA.PA)|
|Madrigal Pharmaceuticals (MDGL)|
|Perspectum Diagnostics PRIVATE|
|Stero Therapeutics PRIVATE|
|Zafgen, Inc (ZFGN)|
Event sponsors include Business Wire and Lowenstein Sandler.
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.